Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit.
Anne Grete SembSilvia RollefstadEirik IkdahlGrunde WibetoeJoseph SextonCindy CrowsonPiet van RielGeorge KitasIan GrahamSolbritt Rantapää-DahlqvistGeorge Athanasios KarpouzasElena MyasoedovaMiguel Angel González-GayPetros P SfikakisMaria G G TektonidouArgyro LazariniDimitrios VassilopoulosBindee KuriyaCarol HitchonMaria Simona StoenoiuPatrick DurezVirginia Pascual-RamosDionicio Ángel Galarza-DelgadoPompilio FaggianoDurga Prasanna MisraAndrew A BorgRong MuErkin M MirrakhimovDiane GhetaKaren DouglasVikas AgarwalSvetlana MyasoedovaLev KrouglyTatiana V PopkovaAlena TuchyňováMichal TomcikMichal VrablikJiri LastuvkaPavel HorakHelena Kaspar MedkovaAnne M Kerolanull nullPublished in: RMD open (2021)
CVD preventive medication use and prevalence of ASCVD were higher in RA-DM than in RAwoDM, and lipid goals were also more frequently obtained in RA-DM. Lessons may be learnt from CVD prevention programmes in DM to clinically benefit patients with RA .